Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Single- And Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BMS-986165 in Healthy Chinese Subjects

Next Previous
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Single- And Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BMS-986165 in Healthy Chinese Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Jun 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deucravacitinib (Primary)
  • Indications Autoimmune disorders; Crohn's disease; Inflammatory bowel diseases; Liver disorders; Lupus nephritis; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Systemic lupus erythematosus; Ulcerative colitis
  • Focus Pharmacokinetics
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 25 Oct 2019 Status changed from active, no longer recruiting to completed.
    • 09 Sep 2019 Planned End Date changed from 25 Jan 2020 to 28 Sep 2019.
    • 09 Sep 2019 Planned primary completion date changed from 9 Sep 2019 to 28 Sep 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top